One Anastomosis Gastric Bypass (OAGB) Explained: A Complete Patient Guide

What is one anastomosis gastric bypass?

One anastomosis gastric bypass, widely known as the mini gastric bypass, takes the proven concept of the gastric bypass and simplifies it. Like the Roux-en-Y gastric bypass, it creates a small stomach pouch and reroutes food past most of the stomach and the entire duodenum, which drives both restriction and powerful hormonal changes. The difference is in the plumbing: OAGB uses a single intestinal connection (one anastomosis) rather than the two connections of a Roux-en-Y.

That single change has real consequences. It shortens operative time, removes one mesenteric defect, and lowers several early complication rates, while producing weight loss and diabetes remission comparable to the Roux-en-Y. But simpler does not mean identical, and the differences are exactly what should drive the decision between the two operations. OAGB is now the third most common bariatric procedure in the world and is formally recognized by both the ASMBS and IFSO (Ramos et al., Obesity Surgery, 2020; De Luca et al., Obesity Surgery, 2021).

Who qualifies?

The 2022 ASMBS and IFSO indications recommend metabolic and bariatric surgery for a BMI of 35 or higher regardless of other conditions, for a BMI of 30 to 35 with a metabolic disease such as type 2 diabetes, and at a lower threshold (generally BMI 27.5 or above) for patients of Asian descent (Eisenberg et al., Surgery for Obesity and Related Diseases, 2022).

OAGB is considered especially well suited to:

• Patients with very high BMI, including super-obesity (BMI of 50 or above), where expert consensus supports it as a single-stage operation.
• Patients with type 2 diabetes who benefit from a strong metabolic effect.
• Patients with weight regain after a prior sleeve gastrectomy or gastric band (Kermansaravi et al., Obesity Surgery, 2022).

Certain conditions are specific contraindications to OAGB. Expert Delphi consensus reached agreement that OAGB should not be offered to patients with severe GERD (grade C or D esophagitis), Barrett's esophagus, or intestinal metaplasia of the stomach. For those patients, the Roux-en-Y configuration, which diverts bile away from the pouch and esophagus, is the appropriate choice. Active smoking is also considered a contraindication (Kermansaravi et al., Obesity Surgery, 2022; Ramos et al., Obesity Surgery, 2020).

The procedure: one connection instead of two

Both operations begin the same way, with a small gastric pouch connected to the small intestine, bypassing most of the stomach and the duodenum. The critical difference is what happens next.

In a Roux-en-Y gastric bypass, the small intestine is divided and rearranged into two channels joined by two connections: a Roux (food) limb carries food from the pouch, a separate biliopancreatic limb carries bile and enzymes, and the two meet downstream at a second connection (the jejunojejunostomy). This is the Y-shaped configuration with three limbs and two anastomoses.

In one anastomosis gastric bypass, that second connection is eliminated. The surgeon creates a longer, narrower gastric pouch (about 12 to 18 cm, calibrated over a 36 to 40 French bougie), then measures a segment of jejunum (commonly 150 to 200 cm) from the ligament of Treitz and brings a single loop of intestine up to the pouch. One connection, one anastomosis. Food flows from the pouch down the loop, and bile and pancreatic enzymes travel through the bypassed limb and join it from the other direction, mixing downstream (Robert et al., Lancet, 2019; Kermansaravi et al., Obesity Surgery, 2021).

The result is one fewer intestinal connection, one fewer mesenteric defect, and a shorter operation. In the MBSAQIP national database, operative time averaged about 99 minutes for OAGB versus 126 minutes for RYGB; in a separate 47,384-patient analysis it was about 101 versus 132 minutes (Cornejo et al., Surgical Endoscopy, 2024; Mocanu et al., Obesity Surgery, 2023). Most patients stay one to two nights and return to normal activities within two to four weeks.

How it works

Both operations act through the same core mechanisms: restriction, hormonal reprogramming, and malabsorption, differing in degree.

The small pouch limits meal volume. The larger driver is hormonal: delivering food rapidly to the jejunum triggers a surge in the fullness hormones GLP-1 and PYY, improves insulin sensitivity, and stimulates insulin secretion, which is why blood sugar often improves within days, before major weight loss (Delko et al., Surgical Endoscopy, 2024).

Two differences distinguish OAGB. First, the longer, narrower pouch slows the rate at which food enters the intestine, which tends to reduce early dumping symptoms. Second, the biliopancreatic limb is typically longer (150 to 200 cm versus 50 to 100 cm in a standard RYGB), which adds a genuine malabsorptive component. In YOMEGA this showed up as significantly more diarrhea and higher steatorrhea in the OAGB group, contributing to weight loss but also to nutritional risk (Robert et al., Lancet, 2019).

Results: weight loss and health improvements

Weight loss with OAGB is comparable to, and by some measures slightly greater than, RYGB. The YOMEGA randomized trial found non-inferiority at 2 years, and its 5-year extension confirmed durability, with excess BMI loss of about 75.6% for OAGB versus 71.4% for RYGB (Robert et al., Lancet, 2019; Robert et al., Lancet Diabetes & Endocrinology, 2024). A meta-analysis of randomized trials found higher excess weight loss after OAGB at 12 months, with no significant difference at later time points (Li et al., Obesity Surgery, 2023).

Long-term data are now robust. A systematic review of studies with at least 10 years of follow-up (1,750 patients) reported weighted mean total weight loss of about 31% at 10 years, and a separate meta-analysis found roughly 32% total weight loss and about 76% excess weight loss at 10 years (Abu-Abeid et al., Obesity Surgery, 2026; Azizi et al., Journal of Gastrointestinal Surgery, 2026). A single-center 10-year series reported about 69% excess weight loss (Makkapati et al., Obesity Surgery, 2025).

Comorbidity improvement is dramatic and comparable to RYGB. Type 2 diabetes remission ranges from about 71 to 90% at 10 years, with reported long-term resolution of hypertension around 57 to 85% and obstructive sleep apnea around 85 to 89% (Abu-Abeid et al., Obesity Surgery, 2026; Makkapati et al., Obesity Surgery, 2025). In YOMEGA, HbA1c reduction was numerically greater with OAGB at 2 years, and diabetes remission was similar between groups at 5 years (Robert et al., Lancet, 2019; Robert et al., Lancet Diabetes & Endocrinology, 2024). Bariatric surgery overall is associated with roughly a 50% reduction in all-cause mortality and a median life-expectancy gain of about 6 years.

Risks and complications: where the two procedures differ most

Overall safety is excellent, with perioperative mortality in the range of 0.03 to 0.2% for metabolic surgery generally (Eisenberg et al., Surgery for Obesity and Related Diseases, 2022). In the MBSAQIP database, OAGB had significantly lower rates of overall complications, readmission, and reoperation than RYGB at 30 days (Cornejo et al., Surgical Endoscopy, 2024; Arshad et al., Surgery for Obesity and Related Diseases, 2024). The long-term complication profile is where the two operations diverge most.

Bile reflux is the central controversy. Because OAGB uses a loop rather than a Roux-en-Y configuration, bile can travel back toward the pouch and esophagus. A meta-analysis of 87 studies (27,775 patients) found a 6% rate of new-onset reflux, 15% esophagitis, and 1% Barrett's esophagus after OAGB, with new-onset reflux significantly higher than after RYGB (Esparham et al., Obesity Surgery, 2023). A prospective study using objective testing found bile in the pouch in 48%, anastomositis in 38%, esophagitis in 34%, and Barrett's in 6% at a mean of about 4 years, even in asymptomatic patients (Felsenreich et al., Surgical Endoscopy, 2025). In YOMEGA at 5 years, clinical GERD occurred in 41% of OAGB patients versus 18% of RYGB patients (Robert et al., Lancet Diabetes & Endocrinology, 2024). By contrast, the Roux-en-Y configuration essentially eliminates bile reflux, and GERD symptoms improve after RYGB. This is the single biggest advantage of RYGB over OAGB.

Marginal ulcers. The literature is mixed. Some series report rates around 10% after OAGB, and one meta-analysis of randomized trials found marginal ulcers more common after OAGB than RYGB. Other meta-analyses find no significant difference, and the 10-year systematic review cites a range of about 1 to 5%, comparable to RYGB, with smoking and poor PPI adherence as key risk factors (Ahmed et al., Obesity Surgery, 2025; Magouliotis et al., Obesity Surgery, 2019; Abu-Abeid et al., Obesity Surgery, 2026). Most are managed with proton pump inhibitors.

Internal hernias. This favors OAGB. With fewer mesenteric defects, internal hernias are less common than after RYGB. Meta-analysis found significantly higher internal hernia and bowel obstruction rates with RYGB, and one long-term comparison reported 8.8% after RYGB versus 3.9% after OAGB (Magouliotis et al., Obesity Surgery, 2019; Abu-Abeid et al., Obesity Surgery, 2026).

Nutritional complications. The longer biliopancreatic limb increases malabsorption. In YOMEGA, about 21% of serious adverse events in the OAGB group were nutritional, versus none in the RYGB group, and some patients required conversion to RYGB for malnutrition (Robert et al., Lancet, 2019). Vitamin D deficiency is more prevalent after OAGB, making fat-soluble vitamin monitoring essential (Heinonen et al., Obesity, 2023).

Dumping syndrome. Early dumping was significantly less common after OAGB in YOMEGA at 3 months (8.4% versus 23.9%), with no significant difference by 2 years (14% versus 15.4%) (Robert et al., Lancet, 2019).

Conversion to Roux-en-Y. In YOMEGA, about 8% of OAGB patients were converted to RYGB by 5 years, primarily for reflux, ulcers, or both; long-term series report conversion or revisional surgery in roughly 3 to 6% of patients (Robert et al., Lancet Diabetes & Endocrinology, 2024; Abu-Abeid et al., Obesity Surgery, 2026).

The bottom line: OAGB versus Roux-en-Y

These two operations produce similar weight loss and similar metabolic benefit. The differences are in the details.

OAGB advantages: shorter operative time, simpler technique, fewer early complications, lower internal hernia and bowel obstruction risk, and less early dumping.

RYGB advantages: essentially eliminates bile reflux, offers better reflux protection, carries less malabsorption and fewer nutritional complications, and has the longest track record.

If you have significant GERD, esophagitis, or Barrett's esophagus, the Roux-en-Y is the right choice. If you do not have reflux and want a simpler operation with comparable metabolic power, OAGB is an excellent option. The honest summary is that the trade-off is reflux.

Life after surgery

Life after OAGB follows the same principles as after RYGB. Diet advances in stages: clear liquids, purees, soft foods, and regular food by six to eight weeks. Protein comes first at every meal (at least 60 to 80 grams per day), no drinking with meals, no carbonation, no concentrated sugar, and at least 64 ounces of water per day.

Vitamins are lifelong and non-negotiable: a bariatric multivitamin, calcium citrate, vitamin D, vitamin B12, and iron as needed. Because the bypassed limb is longer, fat-soluble vitamin and iron monitoring is especially important, with blood work every 3 to 6 months in the first year and at least annually thereafter (Ramos et al., Obesity Surgery, 2020; Heinonen et al., Obesity, 2023). Given the bile reflux concern, regular endoscopic surveillance is recommended, a monitoring requirement that does not apply to Roux-en-Y patients (De Luca et al., Obesity Surgery, 2021). Aim to build to at least 150 minutes of exercise per week, and keep long-term follow-up with the surgical team, which is one of the strongest predictors of durable results.

If you are comparing OAGB with a traditional Roux-en-Y bypass and live in South Florida, see gastric bypass surgery in Miami for how evaluation and surgery are handled at our practice.

Frequently Asked Questions

What is the difference between a mini gastric bypass and a Roux-en-Y gastric bypass?

Both create a small stomach pouch and bypass most of the stomach and the duodenum. The mini gastric bypass (OAGB) uses one intestinal connection and a loop of intestine, while the Roux-en-Y uses two connections in a Y-shaped configuration. OAGB is faster and simpler with fewer early complications, but the Roux-en-Y protects better against bile reflux (Robert et al., Lancet, 2019).

Is mini gastric bypass safer than Roux-en-Y?

In large national database studies, OAGB had shorter operative times and lower rates of overall 30-day complications, readmission, reoperation, and bowel obstruction than RYGB (Cornejo et al., Surgical Endoscopy, 2024; Arshad et al., Surgery for Obesity and Related Diseases, 2024). However, OAGB carries higher long-term risks of bile reflux and nutritional deficiency, so "safer" depends on the individual patient and time horizon.

How much weight will I lose with mini gastric bypass?

Weight loss is comparable to Roux-en-Y. Randomized data show excess BMI loss around 75% at 5 years, and 10-year series show roughly 31% total weight loss and about 64 to 76% excess weight loss (Robert et al., Lancet Diabetes & Endocrinology, 2024; Abu-Abeid et al., Obesity Surgery, 2026).

Does mini gastric bypass cause bile reflux?

It can. This is the main concern with OAGB. Meta-analysis reports about 6% new-onset reflux and 15% esophagitis, and objective testing has found bile in the pouch in nearly half of patients even without symptoms (Esparham et al., Obesity Surgery, 2023; Felsenreich et al., Surgical Endoscopy, 2025). Patients with pre-existing severe reflux or Barrett's esophagus should not have OAGB.

Is mini gastric bypass good for diabetes?

Yes. Type 2 diabetes remission is comparable to Roux-en-Y, ranging from about 71 to 90% at 10 years, and HbA1c improves rapidly after surgery (Abu-Abeid et al., Obesity Surgery, 2026; Robert et al., Lancet, 2019).

Can a mini gastric bypass be converted to a Roux-en-Y later?

Yes, and conversion is one of its advantages. If persistent bile reflux or a marginal ulcer develops, OAGB can be converted to a Roux-en-Y, which typically resolves the reflux. About 8% of patients in the YOMEGA trial were converted by 5 years (Robert et al., Lancet Diabetes & Endocrinology, 2024).

What vitamins do I need after mini gastric bypass?

Lifelong supplementation with a bariatric multivitamin, calcium citrate, vitamin D, vitamin B12, and iron as needed. Because the bypassed limb is longer, fat-soluble vitamins and iron require particular attention and regular blood-level monitoring (Ramos et al., Obesity Surgery, 2020).